Can early b-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?

Neonatology

Volumn 103, Issue 2, 2013, Pages 118-122

  Lee, Jang Hoon ^a   Shin, Jeong Hee ^b   Park, Kyu Hee ^c   Rhie, Young Jun ^b   Park, Moon Sung ^a   Choi, Byung Min ^b  

^a Ajou University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c CHA University   (South Korea)

Author keywords

B type natriuretic peptide; Patent ductus arteriosus; Predictable usefulness; Preterm infant

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PROSTAGLANDIN SYNTHASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; DISEASE MARKER; ECHOCARDIOGRAPHY; EXTREMELY LOW BIRTH WEIGHT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ANALYTICAL EQUIPMENT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY LIGATION; BLOOD FLOW VELOCITY; CARDIOVASCULAR EQUIPMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEMALE; FLUOROIMMUNOASSAY; MULTIPLE CYCLE TREATMENT; ONSET AGE; PREDICTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; UPREGULATION;

DUCTUS ARTERIOSUS, PATENT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84869867073     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000343034     Document Type: Article

References (18)

1. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM: Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina neonatologists association. Pediatrics 1999; 104: 1345-1350.
2. Jhaveri N, Moon-Grady A, Clyman RI: Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010; 157: 381-387, 387.e1.
3. Laughon M, Bose C, Benitz WE: Patent ductus arteriosus management. What are the next steps? J Pediatr 2010; 157: 355-357.
4. Kwinta P, Rudzinski A, Kruczek P, Kordon Z, Pietrzyk JJ: Can early echocardiographic findings predict patent ductus arteriosus? Neonatology 2009; 95: 141-148.
5. Sehgal A, McNamara PJ: Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr 2009; 168: 907-914.
6. Tosse V, Pillekamp F, Verde P, Hadzik B, Sabir H, Mayatepek E, Hoehn T: Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants. Neonatology 2012; 101: 260-266.
7. Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG, Bucher HU, Buhrer C, Arlettaz R, Wellmann S: Plasma C-terminal pro-endothelin-1 and the natriuretic propeptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus. Neonatology 2012; 101: 116-124.
8. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
9. Cowie MR, Mendez GF: BNP and congestive heart failure. Prog Cardiovasc Dis 2002; 44: 293-321.
10. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW: Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115: e255-e261.
11. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T: Role of plasma Btype natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25: 709-713.
12. Lee HS, Choi WS, Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW: Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants. J Korean Soc Neonatol 2004; 11: 44-53.
13. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M: B-type natriuretic peptide to predict ductus intervention in infants ! 28 weeks. Pediatr Res 2008; 64: 286-290.
14. da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA: Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006; 117: 2183-2189.
15. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS: The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005; 147: 38-42.
16. Chen S, Tacy T, Clyman R: How useful are b-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol 2010; 30: 780-785.
17. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR: B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010; 157: 79-84.
18. Mannarino S, Garofoli F, Mongini E, Cerbo RM, Codazzi AC, Tzialla C, Mazzucchelli I, Perotti G, Tinelli C, De Silvestri A, Manzoni P, Stronati M: BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev 2010; 86: 295-298.